Project
A coordinated approach to scaling up access to HIV prevention products
BioPIC is pioneering an integrated and adaptable approach to introducing new HIV prevention products to people who need them, with a focus on injectable cabotegravir (CAB) for PrEP.
The HIV response needs coordination and innovation in product delivery now.
The HIV prevention products that exist today hold the potential to curb incidence. But knowledgeable observers, drawing lessons from the slow roll out and low uptake of oral PrEP in the early years of its availability, know that coordination must be intensified. Without it, highly efficacious products never reach the populations that need it.
The BioPIC collaboration involves civil society, donors, researchers, policy makers, implementers and normative agencies such as WHO and UNAIDS, is made possible through the generous support of the Bill & Melinda Gates Foundation, and was established in partnership with AVAC, CHAI and ViiV Healthcare.
BioPIC developed the Adaptable Product Introduction Framework for all stakeholders involved in product introduction, from clinical research to rollout in low- and middle-income countries. The framework prioritizes activities that must begin in parallel to phase III clinical trials. Stakeholders with a role in early phase product development may also benefit from these considerations with better coordination around anticipated needs.
Plan to provide global and national bodies with needed evidence on safety and efficacy:
Understand resource needs and the impact of CAB-LA:
Enable programs to quickly move from small projects to scale:
Identify methods to support high uptake and continued use:
An ongoing series of think tanks, conducted by BioPIC, are generating key insights for people-centered product delivery. Coordinating Implementation Science for CAB for PrEP
Find details on each topic including reports, findings and additional resources on PrEPwatch.org’s dedicated BioPIC page, featuring an archive of past think tanks. Visit PrEPWatch.org events for upcoming think tanks.
For additional assistance, reach out to Cat Verde Hashim at catherine@avac.org.
poster
An analysis presented at IAS2024, HIV Pre-Exposure Prophylaxis Policies Worldwide, by the Georgetown University Center for Global Health Policy & Politics has found 69% of 194 countries reviewed have approved at least one PrEP product. But only 52% of the countries reviewed follow WHO guidance on PrEP eligibility with regulatory approvals and national policies that support PrEP eligibility for all populations or people at risk.
website
The one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
report
AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered.